Position
Managing Director
Company
HaemaLogiX
SydneyManufacturingBiotechnologyHealth CareTherapeuticsDescription
HaemaLogiX has appointed Dr Chris Baldwin as Chief Executive Officer and Managing Director, effective from January 5, 2026. His leadership is expected to enhance the company’s initiatives as it progresses its clinical programs and prepares for significant milestones.
Other recent leadership changes in Therapeutics and Manufacturing
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Bristol Myers Squibb Appoints Harald Hampel as Senior VP Worldwide Head of Medical Affairs. (February 9, 2026)
- Jubilant Pharmova Appoints Daniel J. O’Connor as Chief Executive Officer (December 2, 2025)
- Flashpoint Therapeutics Appoints Venkat R. Krishnamurthy as Chief Scientific Officer (January 14, 2026)
- CLn Skin Care Appoints Ken Curley as Chief Commercial Officer (January 14, 2026)
- Bioretec Appoints Tuukka Paavola as Chief Financial Officer (January 15, 2026)
- Veristat Appoints Kim McLean Boericke as Chief Executive Officer (January 13, 2026)
Who to call at HaemaLogiX, and when
A new leader at HaemaLogiX brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day HaemaLogiX raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at HaemaLogiX, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at HaemaLogiX. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment HaemaLogiX changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
HaemaLogiX changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.